Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;13(8):525-41.
doi: 10.1038/nrc3565.

Gene-engineered T cells for cancer therapy

Michael H Kershaw  1 , Jennifer A Westwood, Phillip K Darcy
Affiliations
Review

Gene-engineered T cells for cancer therapy

Michael H Kershaw et al. Nat Rev Cancer. 2013 Aug.

Abstract

T cells have the capacity to eradicate diseased cells, but tumours present considerable challenges that render T cells ineffectual. Cancer cells often make themselves almost 'invisible' to the immune system, and they sculpt a microenvironment that suppresses T cell activity, survival and migration. Genetic engineering of T cells can be used therapeutically to overcome these challenges. T cells can be taken from the blood of cancer patients and then modified with genes encoding receptors that recognize cancer-specific antigens. Additional genes can be used to enable resistance to immunosuppression, to extend survival and to facilitate the penetration of engineered T cells into tumours. Using genetic modification, highly active, self-propagating 'slayers' of cancer cells can be generated.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Classification of current anticancer immunotherapies.
    Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Galluzzi L, et al. Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998. Oncotarget. 2014. PMID: 25537519 Free PMC article. Review.
  • In vivo antitumor and antimetastatic effects of flavokawain B in 4T1 breast cancer cell-challenged mice.
    Abu N, Mohamed NE, Yeap SK, Lim KL, Akhtar MN, Zulfadli AJ, Kee BB, Abdullah MP, Omar AR, Alitheen NB. Abu N, et al. Drug Des Devel Ther. 2015 Mar 6;9:1401-17. doi: 10.2147/DDDT.S67976. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25834398 Free PMC article.
  • Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture.
    Ponterio E, De Maria R, Haas TL. Ponterio E, et al. Front Immunol. 2020 Sep 30;11:565631. doi: 10.3389/fimmu.2020.565631. eCollection 2020. Front Immunol. 2020. PMID: 33101285 Free PMC article. Review.
  • Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma.
    Carbone A, Gloghini A, Carlo-Stella C. Carbone A, et al. Blood. 2023 May 4;141(18):2187-2193. doi: 10.1182/blood.2022016590. Blood. 2023. PMID: 36898085 Free PMC article.
  • Switching on the green light for chimeric antigen receptor T-cell therapy.
    Mardiana S, Lai J, House IG, Beavis PA, Darcy PK. Mardiana S, et al. Clin Transl Immunology. 2019 May 5;8(5):e1046. doi: 10.1002/cti2.1046. eCollection 2019. Clin Transl Immunology. 2019. PMID: 31073403 Free PMC article. Review.
See all "Cited by" articles

References

    1. J Immunol. 2009 Nov 1;183(9):5563-74 - PubMed
    1. Cancer Res. 2011 Apr 15;71(8):2871-81 - PubMed
    1. J Clin Invest. 2011 May;121(5):1822-6 - PubMed
    1. Nat Biotechnol. 2002 Dec;20(12):1221-7 - PubMed
    1. Clin Cancer Res. 2012 Apr 15;18(8):2199-209 - PubMed

Publication types

Substances

LinkOut - more resources